LG Life Obtains Korea FDA Approval To Conduct Clinical Trials For Biosimilar Following Celltrion, Hanwha
This article was originally published in PharmAsia News
SEOUL - South Korea's LG Life Sciences became the third local pharma company to obtain Korea FDA approval to conduct clinical trials of its biosimilar, code-named LBEC0101, on the heels of clinical trial clearance for Celltrion and Hanwha Chemicals
You may also be interested in...
Samsung Bioepis has applied for the approval in South Korea of production and sales of SB4, its biosimilar version of Amgen Inc.’s arthritis blockbuster Enbrel (etanercept).
After halting trials of its Rituxan biosimilar last year, Samsung Bioepis is focusing on its Enbrel biosimilar and has begun Phase I trials. Other Korean pharma are developing biosimilars of Enbrel, with Hanwha expecting approval in Korea this year.
SEOUL - LG Life Sciences has reshuffled its top management and named Jung Il-Jae as new CEO and President. Kim In-Chull had served as president of LG Life Sciences since 2006, and took the lead in aggressively moving the company into the biosimilar space. The company said only that Kim will now serve as an advisor to the company